HK1127627A1 - Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker - Google Patents

Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker

Info

Publication number
HK1127627A1
HK1127627A1 HK09106609.1A HK09106609A HK1127627A1 HK 1127627 A1 HK1127627 A1 HK 1127627A1 HK 09106609 A HK09106609 A HK 09106609A HK 1127627 A1 HK1127627 A1 HK 1127627A1
Authority
HK
Hong Kong
Prior art keywords
detection
mage
probes
marker
diagnosis
Prior art date
Application number
HK09106609.1A
Other languages
English (en)
Inventor
Thierry Coche
Olivier Gruselle
Gabriele Anne-Marie Beer
Dennis Salonga
Craig Lawrence Stephens
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of HK1127627A1 publication Critical patent/HK1127627A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK09106609.1A 2006-06-21 2009-07-20 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker HK1127627A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612342.6A GB0612342D0 (en) 2006-06-21 2006-06-21 Method
PCT/EP2007/056219 WO2007147876A2 (en) 2006-06-21 2007-06-21 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker

Publications (1)

Publication Number Publication Date
HK1127627A1 true HK1127627A1 (en) 2009-10-02

Family

ID=36803668

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09106609.1A HK1127627A1 (en) 2006-06-21 2009-07-20 Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker

Country Status (28)

Country Link
US (1) US8936919B2 (hr)
EP (1) EP2041308B1 (hr)
JP (2) JP2009540812A (hr)
KR (1) KR101455589B1 (hr)
CN (1) CN101506383B (hr)
AU (1) AU2007263019B2 (hr)
BR (1) BRPI0713599A2 (hr)
CA (1) CA2656909A1 (hr)
CO (1) CO6140072A2 (hr)
CY (1) CY1113290T1 (hr)
DK (1) DK2041308T3 (hr)
EA (1) EA016347B1 (hr)
ES (1) ES2389513T3 (hr)
GB (1) GB0612342D0 (hr)
HK (1) HK1127627A1 (hr)
HR (1) HRP20120761T1 (hr)
IL (1) IL195975A (hr)
MA (1) MA30565B1 (hr)
MX (1) MX2008016493A (hr)
MY (1) MY147511A (hr)
NO (1) NO20085290L (hr)
NZ (1) NZ573809A (hr)
PL (1) PL2041308T3 (hr)
PT (1) PT2041308E (hr)
SI (1) SI2041308T1 (hr)
UA (1) UA95956C2 (hr)
WO (1) WO2007147876A2 (hr)
ZA (1) ZA200810695B (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100085917A (ko) 2007-09-17 2010-07-29 온코메틸롬 사이언시즈 에스에이 개선된 ｍａｇｅ-ａ 발현 검출법
US8987423B2 (en) * 2010-07-22 2015-03-24 Glaxosmithkline Biologicals, S.A. MAGE antigen binding proteins
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
EP0871765B1 (en) * 1994-03-01 2001-11-28 Ludwig Institute For Cancer Research Determination of cancerous conditions by mage gene expression
US5985571A (en) * 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
DK1659179T3 (da) * 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
US6710172B1 (en) * 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
JP3603138B2 (ja) * 2000-02-18 2004-12-22 独立行政法人理化学研究所 細胞死抑制タンパク質
US6358679B1 (en) * 2000-08-24 2002-03-19 Pe Corporation (Ny) Methods for external controls for nucleic acid amplification
US6635425B2 (en) * 2001-01-05 2003-10-21 Molecular Staging, Inc. 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
AU2002365291B2 (en) 2001-11-29 2007-11-01 Dandrit Biotech A/S Pharmaceutical composition for inducing an immune response in a human or animal
EP1572105B1 (en) * 2002-11-14 2011-08-31 John Wayne Cancer Institute Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Also Published As

Publication number Publication date
DK2041308T3 (da) 2012-10-08
JP5705191B2 (ja) 2015-04-22
MA30565B1 (fr) 2009-07-01
WO2007147876A2 (en) 2007-12-27
GB0612342D0 (en) 2006-08-02
IL195975A (en) 2012-08-30
EA200802356A1 (ru) 2009-06-30
CN101506383A (zh) 2009-08-12
IL195975A0 (en) 2009-09-01
EP2041308A2 (en) 2009-04-01
PT2041308E (pt) 2012-10-09
JP2013046630A (ja) 2013-03-07
KR101455589B1 (ko) 2014-10-28
MX2008016493A (es) 2009-05-21
ZA200810695B (en) 2014-03-26
EA016347B1 (ru) 2012-04-30
NO20085290L (no) 2009-01-19
EP2041308B1 (en) 2012-07-11
CN101506383B (zh) 2013-08-28
UA95956C2 (uk) 2011-09-26
NZ573809A (en) 2011-12-22
WO2007147876A3 (en) 2008-05-15
ES2389513T3 (es) 2012-10-26
PL2041308T3 (pl) 2012-11-30
US20120040341A1 (en) 2012-02-16
SI2041308T1 (sl) 2012-10-30
CY1113290T1 (el) 2016-04-13
KR20090034900A (ko) 2009-04-08
HRP20120761T1 (hr) 2012-10-31
BRPI0713599A2 (pt) 2012-11-06
MY147511A (en) 2012-12-31
CO6140072A2 (es) 2010-03-19
JP2009540812A (ja) 2009-11-26
AU2007263019B2 (en) 2012-11-08
US8936919B2 (en) 2015-01-20
CA2656909A1 (en) 2007-12-27
AU2007263019A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
WO2011008262A9 (en) Methods and apparatus for diagnosis and/or prognosis of cancer
EP2070464A4 (en) SENSOR POSITION DETECTION SYSTEM AND SENSOR DETECTION POSITION DETERMINATION METHOD
EP2370813A4 (en) MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER
HK1172931A1 (zh) 可用於檢測 突變的方法、引物、探針和試劑盒
EP2419737A4 (en) HISTON MODIFYING PATTERN FOR CLINICAL DIAGNOSIS AND FORECASTING CANCER
EP1937816A4 (en) CANCER DIAGNOSTIC MARKERS AND USE
PT3106875T (pt) Método para a deteção de cancro
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE
EP1853729A4 (en) METHOD AND PROBES FOR DETECTING CANCER CANCER
EP2052089A4 (en) EMBRYONIC STEM CELL MARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS
ZA200808669B (en) Methods of treating, diagnosing or detecting cancer
EP2115458A4 (en) METHOD FOR DIAGNOSIS OF HEALTH CONDITIONS FOR OVARIAL CARCINOMA AND THE RISK OF HEALTH CONDITIONS IN OVARIAL CARCINOMA
EP2319924A4 (en) POLYPEPTIDE MARKER FOR THE DIAGNOSIS OF ARTERIOSCLEROSIS, METHOD FOR DETECTION OF ARTERIOSCLEROSIS USING THE MARKER OR SIMILAR, AND DIAGNOSTIC KIT FOR ARTERIOSCLEROSIS
EP2331711A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER AND DETERMINATION OF THE TOTAL AND NON-DISABLED SURVIVAL PERIOD OF CANCER PATIENTS
HK1151828A1 (en) Primer set and probe for detection of human papillomavirus
EP2011871A4 (en) PRIMER AND PROBE FOR THE DETECTION OF MYCOBACTERIUM INTRACELLULARE AND METHOD FOR THE DETECTION OF MYCOBACTERIUM INTRACELLULARE USING THE PRIMER AND THE PROBE
GB2434447B (en) Fluorescent probe for the detection of corrosion
EP1914318A4 (en) METHOD FOR DETECTING THICK-ARMED CANCER MARKERS
HK1127627A1 (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3 marker
EP2495318A4 (en) PROBE FOR DETECTION OF POLYMORPHISM OF THE MPL GENE AND USE THEREOF
HK1157395A1 (en) Primer and probe for detection of mycobacterium intracellulare, and method for detection of mycobacterium intracellulare using the primer or the probe
ZA200808600B (en) Methods and compositions for the detection and treatment of cancers
EP2334813A4 (en) METHOD AND KITS FOR DIAGNOSIS OF RYR1-DEFICENT DISEASES
CR10532A (es) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3- marker
EP2012128A4 (en) METHOD FOR DETERMINING THE PROGNOSIS OF PROSTATE CANCER AND DIAGNOSTIC AGENT FOR USE IN THE PROCESS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170621